I have a fondness for the movies and I perform a function in the biotechnology market, so it’s a bonus when I can combine the two. I’ve written about the correlation between the movie and drug businesses before, so indulge…
Category Archives: Deals
Licensing or Acquisition? Big Pharma Shares How They (and YOU) Decide
February 8, 2012 – 6:47 pm
When I was at the Biocom Global Life Science Partnering Conference last week, one of the more interesting debates I heard was about whether it’s better to in-license an asset or acquire the whole company.
He Said What?!?! Best Biotech Quotes of 2011
December 29, 2011 – 3:26 pm
As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…
Biotech’s Emerging Giant
May 24, 2011 – 8:08 pm
While attending the China track at this year’s J.P. Morgan conference in January I sat next to a gentleman who was smiling as he scanned the jam-packed penthouse meeting room. Shooting him a questioning glance, he responded with “last year…
Don’t Go Away Mad: BioWorld Analyzes Biotech Break-Ups
May 16, 2011 – 6:14 pm
Big pharma has been none too shy about backing away from biotech deals lately, as the likes of Rigel Pharmaceuticals Inc., Targacept Inc., Metabolex Inc., S*BIO Pte Ltd., Portola Pharmaceuticals Inc., Renovo plc, Arena Pharmaceuticals Inc., Adolor Corp. and others…
Join the Conversation